Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

This trial tests whether adding toripalimab and JS004 (two immune checkpoint drugs) to pre-operative chemotherapy before surgery improves outcomes in patients with limited-stage small cell lung cancer (SCLC). Limited-stage means the cancer is still confined to one side of the chest and has not spread widely. The aim is to shrink the tumor before surgery using this combined approach. **You may be eligible if...** - You are 18 or older with confirmed limited-stage SCLC (confined to one lung area, no widespread spread) - You are healthy enough for surgery and your lung function can handle it - Your tumor is measurable on imaging and expected to be completely removable - Your general health is good (ECOG performance status 0 or 1) - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - Your cancer has spread to other parts of the body - You have had prior systemic treatment for this cancer - You have serious autoimmune disease or other medical conditions making immunotherapy unsafe - Your organs (liver, kidney, blood) are not functioning adequately Talk to your doctor to see if this trial is right for you.